⚠️ Investigational — Not FDA-Approved

Retatrutide is not FDA-approved as of June 2026 and is available only through clinical trials. Interaction information is mechanism-based extrapolation. No retatrutide-specific cannabis data is published.

Choose Your Cannabis Method

About Retatrutide: The GLP-1 Gastric Slowing Effect

As a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, retatrutide is expected to produce gastric slowing at least equivalent to — and potentially exceeding — tirzepatide (dual agonist) and semaglutide (single agonist). Oral cannabis absorption delays are predicted to apply on mechanistic grounds, though clinical pharmacokinetic data in retatrutide patients is not yet available.

MethodAffected by GLP-1?Onset on RetatrutidePrimary Risk
EdiblesYes — significantly delayed2–4+ hours⚠️ Caution
SmokingNo — lung absorption1–10 min (unchanged)🔵 Moderate
VapingNo — lung absorption1–10 min (unchanged)🔵 Moderate
TincturesPartial — depends on techniqueMixed (15 min–4+ hours)🔵 Moderate
CBD OilYes — oral absorption delayed2–4+ hours🔵 Moderate

Check Your Full Medication List

Taking Retatrutide plus other medications? Use InteractSafe to review your complete combination.

Retatrutide + Cannabis Full Profile →

Or open the full interaction checker · Free · No account required

Other GLP-1 Medications